Background Patients with cancer and severe aortic stenosis are often ineligible for surgical aortic valve replacement (SAVR). Patients with
Abstract
Background Patients with cancer and severe aortic stenosis are often ineligible for surgical aortic valve replacement (SAVR). Patients with cancer may likely benefit from emerging transcatheter aortic valve replacement (TAVR), given its minimally invasive nature. Methods and Results The US-based National Inpatient Sample was queried between 2012 and 2015 using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), codes to identify all hospitalized adults (aged ≥50 years), who had a primary diagnosis of aortic stenosis. We examined the effect modification of cancer on the relative use rate, outcomes, and dispositions associated with propensity-matched cohort TAVR versus SAVR. Overall, 47 295 TAVRs (22.6% comorbid cancer) and 113 405 SAVRs (15.2% comorbid cancer) were performed among admissions with aortic stenosis between 2012 and 2015. In the year 2015, patients with cancer saw relatively higher rates of TAVR use compared with SAVR (relative use rateTAVR versus relative use rateSAVR, 67.8% versus 57.2%; P<0.0001).<0.001)
PMID: 31960751 [PubMed - in process]
13:29
Photo
Not included, change data exporting settings to download.
256×256, 6.0 KB
13:29
In reply to this message
pubmed: ctoall&ca or conall
The Role of Angiotensin-Converting Enzyme Inhibitors and β-Blockers in Primary Prevention of Cardiac Dysfunction in Breast Cancer Patients.
The Role of Angiotensin-Converting Enzyme Inhibitors and β-Blockers in Primary Prevention of Cardiac Dysfunction in Breast Cancer Patients.
J Am Heart Assoc. 2020 Jan 21;9(2):e015327
Authors: Brown SA, Okwuosa TM, Barac A, Volgman AS
PMID: 31960742 [PubMed - in process]
13:29
Photo
Not included, change data exporting settings to download.
256×256, 6.0 KB
13:29
In reply to this message
pubmed: ctoall&ca or conall
Multimodality Cardiac Imaging in the Era of Emerging Cancer Therapies.
Multimodality Cardiac Imaging in the Era of Emerging Cancer Therapies.
J Am Heart Assoc. 2020 Jan 21;9(2):e013755
Authors: Biersmith MA, Tong MS, Guha A, Simonetti OP, Addison D
PMID: 31960741 [PubMed - in process]
13:29
Photo
Not included, change data exporting settings to download.
256×256, 6.0 KB
13:29
In reply to this message
pubmed: ctoall&ca or conall
Reverse Cardio-Oncology: Cancer Development in Patients With Cardiovascular Disease.
Reverse Cardio-Oncology: Cancer Development in Patients With Cardiovascular Disease.
J Am Heart Assoc. 2020 Jan 21;9(2):e013754
Authors: Aboumsallem JP, Moslehi J, de Boer RA
PMID: 31960736 [PubMed - in process]
13:29
Photo
Not included, change data exporting settings to download.
256×256, 6.0 KB
13:29
In reply to this message
pubmed: ctoall&ca or conall
Precise safety pharmacology studies of lapatinib for onco-cardiology assessed using in vivo canine models.
Related Articles
Precise safety pharmacology studies of lapatinib for onco-cardiology assessed using in vivo canine models.
Sci Rep. 2020 Jan 20;10(1):738
Authors: Ando K, Wada T, Cao X
Comments
Post a Comment
اكتب تعليق حول الموضوع